Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases
The IMID Forum
- Published
- September 25, 2025
- Duration
- 8:44
- Summary source
- description
- Last updated
- Jun 21, 2026
Discusses Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammat…
Summary
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.
Intelligent report
Sign in to read teasers, or upgrade to Research Pro to commission a new dossier for this episode. Learn more →
Show notes
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.